ImmunityBio Inc. saw its stock price climb sharply on Thursday, extending a run of gains to ten consecutive trading days. The shares closed at $3.95 each, a rise of 30.79 percent for the session.
Investors moved into the stock following the company's report of a preliminary 700 percent jump in full-year 2025 revenues from its drug Anktiva. During the period, the company registered $113 million in revenues from the product.
Anktiva is an immunotherapy for non-muscle invasive bladder cancer that has received approval from the U.S. Food and Drug Administration. In the fourth quarter alone, ImmunityBio posted net revenues of $38.3 million. This figure represents a 431 percent increase from the same quarter one year prior.
The company stated that it continues to see increased sales momentum supporting a trend of increases quarter-over-quarter. It reported a 54 percent quarter-over-quarter unit volume growth rate during fiscal year 2025.
In other recent developments, ImmunityBio has secured approval from the Saudi Food and Drug Authority to sell and market Anktiva, in combination with an immune checkpoint inhibitor, in Saudi Arabia.
Executive Chairman Patrick Soon-Shiong commented on the approval. "This approval represents a significant step forward for lung cancer patients in the Kingdom of Saudi Arabia and a meaningful milestone," Soon-Shiong said. "We hope it will pave the way toward additional approvals across a region where lung cancer claims far too many lives each year."